Pommies Receives Micro-Processing Licence from Health Canada for Greater Toronto Area Facility
The Valens Company (OTCQX: VLNCF) announced that Pommies has received a micro-processing license from Health Canada for its facility in the Greater Toronto Area (GTA). This license extends Valens' manufacturing capabilities across Canada, enhancing distribution efficiency. The GTA Facility offers 30,000 square feet for cannabis-infused beverage production, with an annual capacity of 8 million units. Valens aims to grow its market share in the cannabis beverage category, currently at approximately 9.0%. Commercial operations are expected to commence in early 2022.
- Acquisition of a micro-processing license expands manufacturing capabilities across Canada.
- GTA Facility adds 30,000 square feet for cannabis beverage production.
- Annual production capacity of 8 million units enhances scalability.
- Anticipated growth in market share from 9.0% with ongoing product innovation.
- None.
KELOWNA, BC, Nov. 22, 2021 /PRNewswire/ - The Valens Company Inc. (TSX: VLNS) (OTCQX: VLNCF) (the "Company," "The Valens Company" or "Valens"), a leading manufacturer of cannabis products, today announced that Pommies (otherwise known as Southern Cliff Brands) has been issued a micro-processing licence from Health Canada for its manufacturing facility located in the Greater Toronto Area (the "GTA Facility"). With this licence, Valens active manufacturing platform now extends from Western to Eastern Canada, increasing speed-to-market capabilities while optimizing distribution cost-savings and efficiencies.
The GTA Facility provides Valens with an additional 30,000 square feet of licensed production and manufacturing space to execute on its cannabis-infused beverage commercialization and distribution strategy. The facility can support 8 million units per year on a single shift and can produce cannabis-infused beverages in both cans and PET bottles across various sizes and formats including carbonated and non-carbonated juices and waters, drops and single shots. The facility is right sized for the Canadian cannabis industry today and was designed with ample space for expansion if and when required, with minimal additional capital expenditures. The facility is strategically positioned north of Toronto and near Pearson International Airport. This positioning provides for optimal shipping into Canada's largest markets while utilizing significant amounts of automation. This is anticipated to enhance margins on beverages as they are currently being manufactured out of Valens' Kelowna campus in Western Canada.
Products developed and manufactured in the GTA facility will utilize Valens' powered by SōRSE™ emulsion technology, resulting in consumer products that are free of cannabis taste and aroma with predictable onset and offset timing. Valens R&D team has been active in formulating new products soon to be available in the Canadian market and is excited to introduce its innovative pipeline into the beverage and other 2.0 and 3.0 categories.
In Q3 2021, Valens' estimated share of the cannabis-infused beverage category grew to approximately
"Despite delays caused by the pandemic, we have achieved a major milestone in our domestic expansion strategy with the receipt of this micro-processing licence," said Tyler Robson, Chief Executive Officer, Co-Founder, and Chair of The Valens Company. "As one of the first companies to launch cannabis-infused beverages in Canada, we quickly learned what was required to succeed in the category – quality and innovation. We have been working tirelessly to strengthen our resources and capabilities to continue successfully serving the cannabis-infused beverage market in Canada. With the ability to utilize the GTA Facility, we are ready to put our best foot forward and lead the category with a variety of exciting new products which will be available to our customers and consumers over the coming quarters."
All production equipment at the GTA Facility is fully operational and is expected to be commissioned in the coming weeks. Valens expects to begin manufacturing, commercializing and shipping products from the GTA Facility in the first fiscal quarter of 2022 and anticipates an increase in utilization over 2022 as the demand for its products continues to grow. Additionally, Pommies expects to imminently submit a sales licence application for the GTA Facility.
The micro-processing licence was issued in accordance with the Cannabis Act and Cannabis Regulations and was based on the approval of the site evidence package that was submitted earlier this year in February.
At Valens, it's Personal.
About The Valens Company
The Valens Company is a leading manufacturer of cannabis products with a mission to bring the benefits of cannabis to the world. The Company provides proprietary cannabis processing services, in addition to best-in-class product development, manufacturing, and commercialization of cannabis consumer packaged goods. The Valens Company's high-quality products are formulated for the medical, health and wellness, and recreational consumer segments, and are offered across all cannabis product categories with a focus on quality and innovation. The Company also manufactures, distributes, and sells a wide range of CBD products in the United States through its subsidiary Green Roads, and distributes medicinal cannabis products to Australia through its subsidiary Valens Australia. In partnership with brand houses, consumer packaged goods companies and licensed cannabis producers around the globe, the Company continues to grow its diverse product portfolio in alignment with evolving cannabis consumer preferences in key markets. Through Valens Labs, the Company is setting the standard in cannabis testing and research and development with Canada's only ISO17025 accredited analytical services lab, named The Centre of Excellence in Plant-Based Science by partner and scientific world leader Thermo Fisher Scientific. Discover more on The Valens Company at http://www.thevalenscompany.com.
Notice regarding Forward Looking Statements
All information included in this press release, including any information as to the future financial or operating performance and other statements of The Valens Company that express management's expectations or estimates of future performance, other than statements of historical fact, constitute forward-looking information or forward-looking statements within the meaning of applicable securities laws and are based on expectations, estimates and projections as of the date hereof. Forward-looking statements are included for the purpose of providing information about management's current expectations and plans relating to the future. Wherever possible, words such as "plans", "expects", "scheduled", "trends", "forecasts", "future", "indications", "potential", "estimates", "predicts", "anticipate", "to establish", "believe", "intend", "ability to", or statements that certain actions, events or results "may", "should", "could", "would", "might", "will", or are "likely" to be taken, occur or be achieved, or the negative of these words or other variations thereof, have been used to identify such forward-looking information. Specific forward-looking statements include, without limitation, all disclosure regarding future results of operations, future outcomes of transactions, economic conditions, and anticipated courses of action. Investors and other parties are advised that there is not necessarily any correlation between the number of SKUs manufactured and shipped and revenue and profit, and undue reliance should not be placed on such information.
The risks and uncertainties that may affect forward-looking statements include, among others, Canadian regulatory risk, Australian regulatory risk, U.S. regulatory risk, U.S. border crossing and travel bans, the uncertainties, effects of and responses to the COVID-19 pandemic, reliance on licenses, expansion of facilities, competition, dependence on supply of cannabis and reliance on other key inputs, dependence on senior management and key personnel, general business risk and liability, regulation of the cannabis industry, change in laws, regulations and guidelines, compliance with laws, limited operating history, vulnerability to rising energy costs, unfavourable publicity or consumer perception, product liability, risks related to intellectual property, product recalls, difficulties with forecasts, management of growth and litigation, many of which are beyond the control of The Valens Company. For a more comprehensive discussion of the risks faced by The Valens Company, and which may cause the actual financial results, performance or achievements of The Valens Company to be materially different from estimated future results, performance or achievements expressed or implied by forward-looking information or forward-looking statements, please refer to The Valens Company's latest Annual Information Form filed with Canadian securities regulatory authorities at www.sedar.com or on The Valens Company's website at www.thevalenscompany.com. The risks described in such Annual Information Form are hereby incorporated by reference herein. Although the forward-looking statements contained herein reflect management's current beliefs and reasonable assumptions based upon information available to management as of the date hereof, The Valens Company cannot be certain that actual results will be consistent with such forward-looking information. The Valens Company cautions you not to place undue reliance upon any such forward-looking statements. The Valens Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law. Nothing herein should be construed as either an offer to sell or a solicitation to buy or sell securities of The Valens Company.
View original content to download multimedia:https://www.prnewswire.com/news-releases/pommies-receives-micro-processing-licence-from-health-canada-for-greater-toronto-area-facility-301429743.html
SOURCE The Valens Company Inc.
FAQ
What recent license was issued to Pommies by Health Canada?
How does the new GTA Facility impact Valens Company?
What is the production capacity of the GTA Facility?
What percentage of the cannabis-infused beverage market did Valens hold in Q3 2021?
When does Valens expect to begin operations at the GTA Facility?
